Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients.

Kevin PrigentCharline LasnonEmilien EzineMélanie JansonNicolas CoudraisElisa JolyLaure CésaireAndrea StefanMichel DepontvilleNicolas Aide

Published in: European journal of nuclear medicine and molecular imaging (2021)

SLRmean is recommended as a prognosticator in melanoma patients under immunotherapy: its increase greater than 25% at 3 months, compared with baseline, was associated with poor outcome after ICIs.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
high resolution
stem cells
patient reported outcomes
bone marrow
mesenchymal stem cells
photodynamic therapy
patient reported
skin cancer